Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830238) titled 'SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia' on Sept. 10.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.
Condition:
B-cell Acute Lymphoblastic Leukemia
Intervention:
Drug: SNC116
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 28
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07830238
Published ...